Tests blood marker link to lung blood clots in ARDS
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at a blood marker (EV-TF) to see whether it helps predict pulmonary embolism—blood clots in the lungs—in people with ARDS who are in the ICU. Results may help doctors better identify who is at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were admitted to the ICU within the last 24 hours
- You have ARDS (a serious lung condition) diagnosed by standard criteria, including low oxygen on a ventilator and lung changes on imaging
- Your heart cause of lung symptoms has been ruled out by an echocardiogram
- The trial testing period starts before you have had a positive COVID-19 PCR in the breathing samples
- You are not already on full-dose (curative) blood-thinner treatment, ECMO, or certain blood-thinning treatments used with kidney-related purification before ICU
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers in the blood and signs of air trapped in the lung tissue of people with acute respiratory distress syndrome (ARDS). It uses CT scans to understand why air leaks happen and if certain lab tests can predict them.
This study checks if certain blood tests can predict which patients with severe chest injuries will develop serious breathing problems or die. Doctors will take blood samples soon after injury to see if these markers help identify high-risk patients early.
This trial tests whether erythropoietin (EPO), a medicine that affects red blood cell production, can help clear extra fluid from the lungs in people with acute respiratory distress syndrome (ARDS). If it works, it could improve breathing and reduce lung fluid buildup during critical illness.
This study looks for proteins in the blood that might help doctors detect a rare lung injury caused by blood transfusions. It uses blood samples from ICU patients to compare those with and without lung problems.
This study is for patients in the ICU with ARDS (a severe lung condition). It looks at biomarkers (special substances in your blood) to help understand different types of ARDS. You do not receive any treatment, but you help researchers learn more about the disease.
This study looks at people with interstitial lung disease (a lung scarring condition) who have new or worsening symptoms that might be caused by a blood clot in the lungs (pulmonary embolism). Doctors want to find better ways to predict which patients actually have a clot, which could lead to earlier and more accurate treatment.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.